Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

NCT00448305 is registered in ClinicalTrials.gov with MediGene as lead sponsor.

NCT NCT00448305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00448305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
Lead sponsor
MediGene
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
March 31, 2011
Enrollment
143 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms